Education
About Us
Working with TipRanks
Follow Us
Indaptus Therapeutics (INDP)
NASDAQ:INDP
Tislelizumab, Decoy20
Pancreatic Adenocarcinoma, Msi-H Cancer, Solid Tumor, Adult, Uc (Urothelial Cancer), Hcc - Hepatocellular Carcinoma, Crc (Colorectal Cancer), Nsclc Non-Small Cell Lung Cancer, Squamous Cell Cancer Of The Head And Neck
Phase I/II
Recruiting
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Nov 18, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Indaptus Therapeutics (INDP) have in its pipeline
INDP is currently developing the following drugs: Tislelizumab, Decoy20. These drug candidates are in various stages of clinical development as the company works toward FDA approval.